Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Tissue repair & recovery research

KLOW Protocol (KLOW): Research Overview

Vendor blend of four peptides. Individual components have literature; the blend does not.

Also known as KLOW · KPV / GHK-Cu / TB-500 / BPC-157 blend

Research use onlyStrongest evidence: controlled clinical trialReviewed
DatabaseReferences

What is KLOW Protocol?

KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).

What is KLOW Protocol researched for?

  • Each peptide contributes distinct biological pathways: GHK-Cu modulates gene expression for tissue repair, TB-500 enhances cellular migration and wound healing, BPC-157 upregulates growth factors for tissue regeneration, and KPV inhibits NF-κB inflammatory pathway.
  • Multi-modal healing addressing tissue through complementary pathways
  • Enhanced tolerability with KPV versus GLOW formulation
  • Single injection convenience factor
  • Collagen stimulation and tissue regeneration

How does KLOW Protocol work?

GHK-Cu, the primary component (50mg/80mg), is a copper peptide that can be irritating locally. Even with KPV's anti-inflammatory properties, some users experience redness and swelling at injection sites. Rotating sites and using lower doses help mitigate reactions.

References

  1. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    Pickart L, Margolina A · International journal of molecular sciences · 2018

    GHK-Cu modulates over 4,000 human genes, stimulates collagen/elastin/GAG synthesis, promotes blood vessel and nerve outgrowth, and supports tissue repair in skin, lung, bone, liver, and stomach.

    PMID 29986520

  2. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth

    Staresinic M, Sebecic B, Patrlj L, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003

    BPC-157 fully improved Achilles tendon recovery biomechanically, functionally, and microscopically; reversed HNE growth inhibition of tendocytes in vitro.

    Animal study · PMID 14554208

  3. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

    Wang X, Liu L, Qi L, et al. · Journal of cellular and molecular medicine · 2021

    Phase I trial in 54 healthy subjects demonstrated recombinant thymosin β4 (TB-500 analog) was well tolerated and safe across ascending IV doses with no significant accumulation.

    Controlled clinical trial · PMID 34346165

  4. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

    Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology · 2008

    KPV inhibits NF-κB activation and reduces intestinal inflammation via PepT1-mediated transport; demonstrated anti-inflammatory effects in murine IBD models.

    Animal study · PMID 18061177

  5. No Published Studies on KLOW Combination N/A

    2024

    No clinical or preclinical studies examine the safety or efficacy of the four-peptide KLOW combination; all evidence is extrapolated from individual component research.